Assessing Azithromycin's Impact on Bronchopulmonary Dysplasia in Preterm Infants
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on May 1st, 2024
|
Hypertriglyceridemia correlates with an increased likelihood of developing atherosclerotic cardiovascular disease, nonalcoholic fatty liver, and acute pancreatitis. The protein APOC3 is implicated in this condition due to its role in impeding the breakdown of triglyceride-rich lipoproteins and chylomicrons. Plozasiran, a small-interfering RNA, targets and degrades mRNA encoding the APOC3 protein. Consequently, a study was undertaken to evaluate its effectiveness in addressing hypertriglyceridemia.
The phase 2 clinical trial involved 226 patients with an average blood triglyceride level of 897 mg/dL. Initially, the average APOC3, HDL, and LDL levels were recorded at 32 mg/dL, 30 mg/dL, and 72 mg/dL, respectively. Among the participants, 68% were undergoing statin therapy, while 48% were on fibrates. Through random assignment, participants were allocated to receive either placebo or three different doses of plozasiran (10 mg, 25 mg, and 50 mg). Subcutaneous injections were administered at enrollment and again after 12 weeks. Researchers noted that four weeks after receiving injections of 25 mg and 50 mg of plozasiran, there was a reduction of over 80% in APOC3 and triglyceride levels from baseline, with the 10 mg dose group showing a reduction of over 60%. Treatment also led to increased HDL levels and reduced cholesterol concentrations. Monitoring for adverse effects revealed that plozasiran, particularly in the highest dose group tested, was associated with worsened glycemic control compared to placebo.
The phase 2 clinical trial involved 226 patients with an average blood triglyceride level of 897 mg/dL. Initially, the average APOC3, HDL, and LDL levels were recorded at 32 mg/dL, 30 mg/dL, and 72 mg/dL, respectively. Among the participants, 68% were undergoing statin therapy, while 48% were on fibrates. Through random assignment, participants were allocated to receive either placebo or three different doses of plozasiran (10 mg, 25 mg, and 50 mg). Subcutaneous injections were administered at enrollment and again after 12 weeks. Researchers noted that four weeks after receiving injections of 25 mg and 50 mg of plozasiran, there was a reduction of over 80% in APOC3 and triglyceride levels from baseline, with the 10 mg dose group showing a reduction of over 60%. Treatment also led to increased HDL levels and reduced cholesterol concentrations. Monitoring for adverse effects revealed that plozasiran, particularly in the highest dose group tested, was associated with worsened glycemic control compared to placebo.